默克公司通过激进的专利扩大了Keytruda独家权, 每年使患者损失超过20万美元. Merck extends Keytruda exclusivity with aggressive patents, costing patients over $200,000 annually.

默克公司使用激进的专利策略延迟仿制药, 每年在美国为患者支付高达208,000美元. Merck maintains high prices for cancer drug Keytruda using aggressive patent strategies to delay generics, costing patients up to $208,000 annually in the U.S. 调查显示,法律网络旨在扩大专属性和利, 而一些患者面临危及生命的延误或购买假冒版本由于无法访问. The investigation reveals a legal network designed to extend exclusivity and profits, while some patients face life-threatening delays or buy counterfeit versions due to inaccessibility.